Diagonal Therapeutics raises $128m for antibodies discovery
04 Apr 2024
Cell Therapy
Preview
Source: Pharmaceutical Technology
Diagonal’s lead programme is being developed for the treatment of hereditary haemorrhagic telangiectasia. Credit: dimid_86 / Shutterstock.com.
Biotechnology company Diagonal Therapeutics has announced its launch, raising $128m through a Series A financing round for its new approach to discovering and developing agonist antibodies.
BVF Partners and Atlas Venture jointly led the financing round with participation from Checkpoint Capital, Frazier Life Sciences, Lightspeed Venture Partners, RA Capital Management, Velosity Capital and Viking Global Investors.
The company plans a new approach to develop antibodies to address the underlying causes of severely debilitating disease.
The funds will be utilised to advance its Diagonal platform and the development of a pipeline of new therapeutics.
The platform merges computational and experimental approaches to detect rare agonist antibodies that can re-activate deficient signalling pathways.
See Also:
Obsidian raises $160.5m to advance TIL cell therapy programme
Preview
Source: Pharmaceutical Technology
Harnessing pharmacovigilance to turn reactive investigation into active discovery
Preview
Source: Pharmaceutical Technology
Diagonal will also use the funds to progress its lead programme for hereditary haemorrhagic telangiectasia (HHT) through clinical proof-of-concept.
In preclinical models, agonist antibodies of Diagonal demonstrated the ability to hinder and reverse the formation of pathological vascular malformations associated with HHT.
The company also discovered antibody candidates against four complex targets, which could pave the way for new treatments for severe diseases such as pulmonary arterial hypertension.
Diagonal Therapeutics co-founder Alex Lugovskoy stated: “We are fundamentally changing how agonist antibody therapies are developed.
“The Diagonal platform allows us to overcome technical limitations that hindered agonist antibody discovery in the past, and we have demonstrated that we can efficiently advance novel drug candidates for diseases where patients have limited or no treatment options.
“Our approach enables us to treat a wide range of disorders where signalling pathways have been disrupted with agonist antibodies that have superior potency and selectivity, tunable and sustained pharmacology, excellent developability and low immunogenicity.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.